keytruda

Merck reported a 6% increase in worldwide sales to $10 billion for the first quarter of 2018 compared to the prior year period. Pharmaceutical sales grew 9% to $8.9 billion driven primarily by growth in oncology, hospital acute care and diabetes. This was partially offset by lower sales in...

Interesting history of Keytruda from Forbes... https://www.forbes.com/sites/davidshaywitz/2017/07/26/the-startling-history-behind-mercks-new-cancer-blockbuster/#49d835d7948d

Merck strengthens its oncology platform by acquiring Viralytics for $394 million Merck has announced its first acquisition in the year 2018. Hope this deal benefits Merck.

Merck said today that the FDA has given consent to review a supplemental Biologics License Application (sBLA) for KEYTRUDA for the treatment of non-Hodgkin lymphoma. http://alph.st/bb41cf87

Why is it a few get rich while thousands are laid off because they've lost billions? Peter & Ken Niraparib Discovery PARP within Merck and then liscenced it out only to become a hit drug for Tesaro...

Merck quarterly profit beat analysts' estimates as demand surged for its oncology drug, Keytruda. Sales of Keytruda nearly tripled to $881 million in the second quarter, beating consensus estimates of $777 million, according to Barclays. First approved in 2014 to treat melanoma, Keytruda has...